MRK May 2024 130.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 03:56PM EDT. Market open.
| Previous close | 1.1500 |
| Open | 1.0200 |
| Bid | 0.6700 |
| Ask | 0.7300 |
| Strike | 130.00 |
| Expiry date | 2024-05-17 |
| Day's range | 0.3400 - 1.0200 |
| Contract range | N/A |
| Volume | |
| Open interest | 11.6k |
Business WireMerck Provides Update on Phase 3 KeyVibe-010 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab as Adjuvant Treatment for Patients With Resected High-Risk Melanoma
RAHWAY, N.J., May 13, 2024--Merck Update on KeyVibe-010 Evaluating Coform of Vibostolimab and Pembrolizumab as Adjuvant Treatment for Patients W/ Resected High-Risk Melanoma
Simply Wall St.Merck's (NYSE:MRK) investors will be pleased with their notable 90% return over the last three years
By buying an index fund, investors can approximate the average market return. But if you pick the right individual...
ZacksInvestors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.
© 2024 Yahoo. All rights reserved.